RedHill Biopharma Ltd (RDHL)

[H2R]

Exciting potential milestones and data points between now and the first quarter of this year in a likely chronological order include:

top-line results from the BEKINDA 24 milligram Phase III GUARD study for gastroenteritis expected this quarter, Q2 2017;

initiation of our confirmatory Phase III study with RHB-105 for the treatment of H. pylori infection also expected this quarter, second quarter of 2017;

top-line results from the BEKINDA 12 milligram Phase II study for IBS-D, irritable bowel syndrome with diarrhea expected in the third quarter;

and a second independent DSMB meeting for the MAP U.S. Phase III study with RHB-104 for Crohn's disease, including an interim efficacy analysis and evaluation of an option for early stop for success for overwhelming efficacy also expected around mid-year.

https://seekingalpha.com/article/4068525-redhill-biopharmas-rdhl-ceo-dror-ben-asher-q1-2017-results-earnings-call-transcript?part=single